How to buy BioDelivery Sciences International stock (BDSI)

BioDelivery Sciences International is a drug manufacturers - specialty & generic business based in the US. BioDelivery Sciences International shares (BDSI) are listed on the NASDAQ and all prices are listed in US Dollars. BioDelivery Sciences International employs 200 staff and has a trailing 12-month revenue of around $166.7 million.

Our top picks for where to buy BioDelivery Sciences International stock

Buy BioDelivery Sciences International stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

BioDelivery Sciences International stock price (NASDAQ: BDSI)

Use our graph to track the performance of BDSI stocks over time.

BioDelivery Sciences International shares at a glance

• Key figures

Information last updated 2023-10-20.

52-week range	$0.00 - $0.00
50-day moving average more info button	$4.96
200-day moving average more info button	$3.88
Wall St. target price	$5.38
PE ratio more info button	6.8171
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$0.82

Is it a good time to buy BioDelivery Sciences International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is BioDelivery Sciences International stock undervalued or overvalued?

Valuing BioDelivery Sciences International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioDelivery Sciences International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioDelivery Sciences International's P/E ratio

BioDelivery Sciences International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, BioDelivery Sciences International shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

BioDelivery Sciences International's PEG ratio

BioDelivery Sciences International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.95. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioDelivery Sciences International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioDelivery Sciences International's EBITDA

BioDelivery Sciences International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $44.5 million.

The EBITDA is a measure of a BioDelivery Sciences International's overall financial performance and is widely used to measure a its profitability.

BioDelivery Sciences International financials

Revenue TTM	$166.7 million
Operating margin TTM	22.27%
Gross profit TTM	$143.3 million
Return on assets TTM	8.22%
Return on equity TTM	57.33%
Profit margin	50.91%
Book value	$1.90
Market Capitalization more info button	$577.1 million

TTM: trailing 12 months

BioDelivery Sciences International share dividends

We're not expecting BioDelivery Sciences International to pay a dividend over the next 12 months.

BioDelivery Sciences International share price volatility

Over the last 12 months, BioDelivery Sciences International's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioDelivery Sciences International's is 0.5551. This would suggest that BioDelivery Sciences International's shares are less volatile than average (for this exchange).

BioDelivery Sciences International overview

BioDelivery Sciences International, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

Frequently asked questions

null
What percentage of BioDelivery Sciences International is owned by insiders or institutions?
Currently 7.58% of BioDelivery Sciences International shares are held by insiders and 68.207% by institutions. How many people work for BioDelivery Sciences International?
Latest data suggests 200 work at BioDelivery Sciences International. When does the fiscal year end for BioDelivery Sciences International?
BioDelivery Sciences International's fiscal year ends in December. Where is BioDelivery Sciences International based?
BioDelivery Sciences International's address is: 4131 ParkLake Avenue, Raleigh, NC, United States, 27612 What is BioDelivery Sciences International's ISIN number?
BioDelivery Sciences International's international securities identification number is: US09060J1060 What is BioDelivery Sciences International's CUSIP number?
BioDelivery Sciences International's Committee on Uniform Securities Identification Procedures number is: 09060J106